BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

Overview Fund Trends Analyst Outlook Journalist POV

12 hedge funds and large institutions have $2.62M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

less ownership

Funds ownership: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

38% less capital invested

Capital invested by funds: $4.23M → $2.62M (-$1.6M)

Holders
12
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$5.21M
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$606K
2
+$283K
3
+$123K
4
UBS Group
UBS Group
Switzerland
+$63K
5
Simplex Trading
Simplex Trading
Illinois
+$47K

Top Sellers

1
-$757K
2
-$660K
3
-$319K
4
Citadel Advisors
Citadel Advisors
Florida
-$282K
5
CT
CMT Trading
Illinois
-$210K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$606K
2
$479K
3
$454K
4
$283K
5
$260K
6
$205K
7
$168K
8
$63K
9
$47K
10
$34K
11
$24K
12
$1K
13
–
14
–
15
–